Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Marcus Matthias Schittenhelm"'
Autor:
Mihada Bajrami Saipi, Alessia Ruiba, Marcus Matthias Schittenhelm, Gunnar Blumenstock, Balázs Győrffy, Serena Fazio, Marlon Hafner, Anna-Lena Ahrens, Lara Aldinger, Vanessa Aellig, François G. Kavelaars, César Nombela-Arrieta, Falko Fend, Peter J. M. Valk, Driessen Christoph, Kerstin Maria Kampa-Schittenhelm
Publikováno v:
Cell Death and Disease, Vol 15, Iss 11, Pp 1-13 (2024)
Abstract Apoptosis-stimulating proteins of p53 (ASPPs) are a family of proteins that modulate key tumor suppressor pathways via direct interaction with p53. Deregulation of these proteins promotes cancer development and impairs sensitivity to systemi
Externí odkaz:
https://doaj.org/article/793637dff01642d6878a7b3b72ca88da
Autor:
Marcus Matthias Schittenhelm, Bianca Walter, Vasileia Tsintari, Birgit Federmann, Mihada Bajrami Saipi, Figen Akmut, Barbara Illing, Ulrike Mau-Holzmann, Falko Fend, Charles Darin Lopez, Kerstin Maria Kampa-Schittenhelm
Publikováno v:
EBioMedicine, Vol 42, Iss , Pp 340-351 (2019)
Background: Apoptosis-stimulating Protein of TP53-2 (ASPP2) is a tumor suppressor enhancing TP53-mediated apoptosis via binding to the TP53 core domain. TP53 mutations found in cancers disrupt ASPP2 binding, arguing for an important role of ASPP2 in
Externí odkaz:
https://doaj.org/article/162a0dcf7af743ecb55394431c13be11
Autor:
Michael Lübbert, Claudia Schmoor, Tobias Berg, Michael Kruszewski, Marcus Matthias Schittenhelm, Katharina Götze, Caroline Pabst, Andrea Kündgen, Tobias Ma, Anna Frey, Kevin Moschallski, Usama-Ur Rehman, Johannes Jung, Justus Duyster, Manfred Jung, Roland Schüle, Ralph Wäsch, Olga Grishina
Publikováno v:
Blood. 140:9087-9088
Autor:
Marcus Matthias Schittenhelm, Mihada Bajrami Saipi, Gunnar Blumenstock, Peter JM Valk, Balazs Györffy, Kerstin Maria Kampa-Schittenhelm
Publikováno v:
Blood. 140:3433-3434
Autor:
Kerstin Maria, Kampa-Schittenhelm, Julia, Frey, Lara A, Haeusser, Barbara, Illing, Ashly A, Pavlovsky, Gunnar, Blumenstock, Marcus Matthias, Schittenhelm
Publikováno v:
Oncotarget
Activating D816 mutations of the class III receptor tyrosine kinase KIT are associated with the majority of patients with systemic mastocytosis (SM), but also core binding factor (CBF) AML, making KIT mutations attractive therapeutic targets for the